The selective 5-HT2A receptor agonist 25CN-NBOH does not affect reversal learning in mice.
Animals
Anxiety
/ drug therapy
Behavior, Animal
/ drug effects
Cognition
Depressive Disorder, Treatment-Resistant
/ drug therapy
Hallucinogens
/ pharmacology
Ligands
Mice
Mice, Inbred C57BL
Receptor, Serotonin, 5-HT2A
/ metabolism
Reversal Learning
/ drug effects
Serotonin 5-HT2 Receptor Agonists
/ pharmacology
Treatment Outcome
Journal
Behavioural pharmacology
ISSN: 1473-5849
Titre abrégé: Behav Pharmacol
Pays: England
ID NLM: 9013016
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
pubmed:
18
2
2021
medline:
22
1
2022
entrez:
17
2
2021
Statut:
ppublish
Résumé
Psychedelic 5-hydroxytryptamine 2A receptor (5-HT2AR) agonists are showing promise in the treatment of psychiatric disorders, such as treatment-resistant depression and anxiety. Human studies suggest that enhanced cognitive flexibility may contribute to their clinical efficacy. Both improvement and impairment of cognitive flexibility has been reported with 5-HT2AR ligands, making the link between 5-HT2AR pharmacology and cognitive flexibility equivocal. We tested the selective 5-HT2AR agonist 25CN-NBOH in healthy male C57BL/6JOlaHsd mice in a touchscreen-based mouse reversal learning test. No effects were observed on acquisition of the new stimulus-reward contingency, learning errors, or perseverative responses during reversal. Our results suggest that 25CN-NBOH does not affect reversal learning in the schedule used in this study.
Identifiants
pubmed: 33595957
doi: 10.1097/FBP.0000000000000626
pii: 00008877-202108000-00009
doi:
Substances chimiques
Hallucinogens
0
Ligands
0
Receptor, Serotonin, 5-HT2A
0
Serotonin 5-HT2 Receptor Agonists
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
448-452Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Amodeo DA, Hassan O, Klein L, Halberstadt AL, Powell SB. (2020). Acute serotonin 2A receptor activation impairs behavioral flexibility in mice. Behav Brain Res. 395:112861.
Amodeo DA, Jones JH, Sweeney JA, Ragozzino ME. (2014). Risperidone and the 5-HT2A receptor antagonist M100907 improve probabilistic reversal learning in BTBR T + tf/J mice. Autism Res. 7:555–567.
Araújo AM, Carvalho F, Bastos M d e L, Guedes de Pinho P, Carvalho M. (2015). The hallucinogenic world of tryptamines: an updated review. Arch Toxicol. 89:1151–1173.
Bissonette GB, Powell EM. (2012). Reversal learning and attentional set-shifting in mice. Neuropharmacology. 62:1168–1174.
Boulougouris V, Glennon JC, Robbins TW. (2008). Dissociable effects of selective 5-HT2A and 5-HT2C receptor antagonists on serial spatial reversal learning in rats. Neuropsychopharmacology. 33:2007–2019.
Brigman JL, Mathur P, Harvey-White J, Izquierdo A, Saksida LM, Bussey TJ, et al. (2010). Pharmacological or genetic inactivation of the serotonin transporter improves reversal learning in mice. Cereb Cortex. 20:1955–1963.
Buchborn T, Lyons T, Knöpfel T. (2017). Tolerance and tachyphylaxis to head twitches induced by the selective 5-HT2A agonist 25CN-NBOH in mice. London ed: Laboratory for Neuronal Circuit Dynamics DoBS, Department of Medicine, Imperial College.
Buchborn T, Lyons T, Knöpfel T. (2018). Tolerance and tachyphylaxis to head twitches induced by the 5-HT2A agonist 25CN-NBOH in mice. Front Pharmacol. 9:17.
Carhart-Harris RL, Goodwin GM. (2017). The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology. 42:2105–2113.
Carhart-Harris RL, Kaelen M, Bolstridge M, Williams TM, Williams LT, Underwood R, et al. (2016). The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychol Med. 46:1379–1390.
Carhart-Harris RL, Leech R, Hellyer PJ, Shanahan M, Feilding A, Tagliazucchi E, et al. (2014). The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci. 8:20.
Carhart-Harris RL, Nutt DJ. (2017). Serotonin and brain function: a tale of two receptors. J Psychopharmacol. 31:1091–1120.
Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX. (2005). Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci. 17:1497–1508.
Clark RA, Shoaib M, Hewitt KN, Stanford SC, Bate ST. (2012). A comparison of InVivoStat with other statistical software packages for analysis of data generated from animal experiments. J Psychopharmacol. 26:1136–1142.
Fantegrossi WE, Gray BW, Bailey JM, Smith DA, Hansen M, Kristensen JL. (2015). Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT 2 A receptors, in mice. Psychopharmacology (Berl). 232:1039–1047.
Furr A, Lapiz-Bluhm MD, Morilak DA. (2012). 5-HT2A receptors in the orbitofrontal cortex facilitate reversal learning and contribute to the beneficial cognitive effects of chronic citalopram treatment in rats. Int J Neuropsychopharmacol. 15:1295–1305.
Hansen M, Phonekeo K, Paine JS, Leth-Petersen S, Begtrup M, Bräuner-Osborne H, Kristensen JL. (2014). Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists. ACS Chem Neurosci. 5:243–249.
Jensen AA, McCorvy JD, Leth-Petersen S, Bundgaard C, Liebscher G, Kenakin TP, et al. (2017). Detailed characterization of the in vitro pharmacological and pharmacokinetic properties of N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine (25CN-NBOH), a highly selective and brain-penetrant 5-HT2A receptor agonist. J Pharmacol Exp Ther. 361:441–453.
Jungaberle H, Thal S, Zeuch A, Rougemont-Bücking A, von Heyden M, Aicher H, Scheidegger M. (2018). Positive psychology in the investigation of psychedelics and entactogens: a critical review. Neuropharmacology. 142:179–199.
King AR, Martin IL, Melville KA. (1974). Reversal learning enhanced by lysergic acid diethylamide (LSD): concomitant rise in brain 5-hydroxytryptamine levels. Br J Pharmacol. 52:419–426.
Kuypers KP, Riba J, de la Fuente Revenga M, Barker S, Theunissen EL, Ramaekers JG. (2016). Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking. Psychopharmacology (Berl). 233:3395–3403.
MacLean KA, Johnson MW, Griffiths RR. (2011). Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol. 25:1453–1461.
Nichols DE. (2016). Psychedelics. Pharmacol Rev. 68:264–355.
Nichols DE, Johnson MW, Nichols CD. (2017). Psychedelics as medicines: an emerging new paradigm. Clin Pharmacol Ther. 101:209–219.
Odland AU, Jessen L, Kristensen JL, Fitzpatrick CM, Andreasen JT. (2021). The 5-hydroxytryptamine 2A receptor agonists DOI and 25CN-NBOH decrease marble burying and reverse 8-OH-DPAT-induced deficit in spontaneous alternation. Neuropharmacology. 183:107838.
Petri G, Expert P, Turkheimer F, Carhart-Harris R, Nutt D, Hellyer PJ, Vaccarino F. (2014). Homological scaffolds of brain functional networks. J R Soc Interface. 11:20140873.
Pokorny T, Duerler P, Seifritz E, Vollenweider FX, Preller KH. (2020). LSD acutely impairs working memory, executive functions, and cognitive flexibility, but not risk-based decision-making. Psychol Med. 50:2255–2264.
Porter RH, Malcolm CS, Allen NH, Lamb H, Revell DF, Sheardown MJ. (2001). Agonist-induced functional desensitization of recombinant human 5-HT2 receptors expressed in CHO-K1 cells. Biochem Pharmacol. 62:431–438.
Umbricht D, Vollenweider FX, Schmid L, Grübel C, Skrabo A, Huber T, Koller R. (2003). Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology. 28:170–181.